Oppenheimer & Co’s Protagonist Therapeutics PTGX Stock Holding History

Oppenheimer & Co’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$233K	Hold	1,900	–	–	﹤0.01%	1593
2026 Q1	$200K	Buy	+1,900	New	+$168K	﹤0.01%	1576

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Oppenheimer & Co's PTGX Position: Q2 2026 in Review

Oppenheimer & Co held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 1,900 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Oppenheimer & Co first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Oppenheimer & Co held 1,900 shares of Protagonist Therapeutics worth $233K as of Q2 2026.
Oppenheimer & Co left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1593 holding.
Oppenheimer & Co first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.